Joby Deal Shifts Blade's Path, But Stock Stalls

Blade Air Mobility's Strategic Shift and Market Outlook

Blade Air Mobility Inc. (NASDAQ: BLDE) has experienced a significant transformation over the past week, marked by a major business decision that could reshape its future. On August 4, Blade announced the sale of its passenger mobility business to Joby Aviation Inc. (NYSE: JOBY) for up to $125 million. This deal sent BLDE stock soaring by 30% initially, but the gains have since been eroded as the company released mixed earnings results.

The sale of the passenger division marks a pivotal shift in Blade’s strategy. The company will transition into a pure-play medical logistics firm and rebrand itself as Strata Critical Medical. This move is aimed at focusing on high-growth areas within the healthcare sector, particularly in non-emergency medical transport (NEMT), organ transfer, and time-critical healthcare logistics.

Despite the positive momentum from the deal, Blade’s recent earnings report revealed some challenges. While the company exceeded revenue expectations, it reported a negative earnings per share of five cents, which was one cent worse than analysts had forecasted. This highlights the ongoing struggle of a company that, while showing promise, is not yet profitable.

The Medical Division: A Stronger Foundation

Blade operates through two primary divisions: Medical and Blade Passenger. The medical division, which includes MediMobility Organ Transport, is the backbone of the company. As of the most recent quarter, nearly 60% of Blade’s revenue and 84% of its EBITDA came from this division. The medical segment also saw an 18% year-over-year (YOY) revenue growth, a stark contrast to the combined 8% YOY revenue decline in the passenger division.

This performance underscores the potential of Blade’s medical logistics business. The company is positioned as a leader in the transportation of human organs for transplant in the U.S., with a growing addressable market estimated at around $1 billion. Blade already controls approximately 30% of this market, indicating strong long-term potential.

Preparing for a Leaner, Profitable Future

The sale of the passenger division is expected to result in a leaner, more predictable business model. With the anticipated $200 million in cash proceeds from the deal, Blade plans to pursue strategic acquisitions and further strengthen its position in the medical logistics sector. Management remains optimistic about the future, citing continued attractive organic growth and the potential for expansion.

However, the transition is not without risks. The sale is structured entirely in Joby stock, which introduces uncertainty related to the future value of the shares. Blade’s management expressed confidence in Joby’s ability to deliver, but the final payout depends on the performance of Joby’s stock, which could be volatile given the pre-revenue status of the company.

Navigating the Uncertainty

The deal is expected to close in the first half of 2026, which adds another layer of uncertainty for investors. This timeline allows for potential fluctuations in the stock price, especially considering the regulatory hurdles involved in such transactions. For now, BLDE stock reflects cautious optimism, with traders likely to look for short-term opportunities.

Investors with a lower risk tolerance may prefer to wait until the deal is closer to completion before making any decisions. On the other hand, those with a higher risk appetite might consider starting to build a position in BLDE as the details of the transaction become clearer.

Looking Ahead

While Blade’s future appears promising, the path to profitability will take time. The company’s focus on medical logistics offers stability and near-term profit potential, but the upside may be capped compared to its previous ambitions in urban air travel. Investors should monitor the progress of the Joby deal closely, as it will play a critical role in shaping Blade’s trajectory.

As the company continues to evolve, the coming months will be crucial in determining whether Blade can successfully transition into a profitable, asset-light medical mobility company. For now, the market remains watchful, balancing hope for long-term growth against the realities of a complex and evolving business landscape.